Canadian Patents & Development Ltd.

Instytut Immunologii I Terapii Doswiadczalnej Pan

Wroclawskie Centrum Badan Eit+ Sp. Z O.o.

Instytut Biologii Medycznej Polskiej Akademii Nauk

Instytut Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk

Port Polski Osrodek Rozwoju Technologii Sp. Z O.o.

Czeslaw Lugowski

Tomasz Niedziela

Harold J Jennings

Jolanta Lukasiewicz

Anna Swierzko

Sabina Koj

Maciej Cedzynski

Anna Maciejewska

Wojciech Jachymek

The present invention relates to an immunogenic and a non-toxic glycoconjugate comprisingLOS-derived oligosaccharide and pertussis toxin, a method of preparing such glycoconjugate, the pharmaceutical composition, a vaccine composition containing such glycoconjugate, and an application of the glycoconjugate. The glycoconjugate is prepared as a vaccine component for protection against infections caused by

[object Object]

The invention relates to bacterial lipopolysaccharide and its components, especially native and chemically modified polysaccharides isolated fromlipopolysaccharides, as well as conjugates of these polysaccharides with carriers and methods for their preparation and methods to use of these substances as ligands for human ficolin-3.

Polysaccharide and derivatives thereof, showing affinity to ficolin-3, method of preparation and use

Antigenic polysaccharides are modified to generate a terminally-located aldehyde group by controlled oxidation of vicinal hydroxyl groups, e.g. of unlinked terminal non-reducing sialic acid residues. In some cases where there is a reducing end group, e.g. of the type N-acetylmannosamine residue, it can be made into the most susceptible site for oxidation by initially reducing it to its open chain hydroxyl form, e.g. N-acetylmannosaminitol. The vicinal hydroxyl oxidation is controlled to yield a reactive aldehyde group which is then covalently linked to a free amino group of a selected protein by reductive amination. The resulting polysaccharide-protein conjugates are soluble and have been found to have enhanced antigenicity compared to the polysaccharide alone. This terminal aldehyde:free amine group reductive amination can be applied to various polysaccharide antigens and various well-tolerated proteins, preferably protein immunogens. For example, meningococcal group A, B and C polysaccharides have been linked to tetanus toxoid to give soluble conjugates which have been found to have advantageous immunogenic properties.

Immunogenic polysaccharide-protein conjugates

Growing community of inventors

Wroclaw, Poland

Czeslaw Lugowski